Bone markers and CKD

My endocrinologist does not use bone markers. He has said that an entire conference could focus on this topic, and that in his view, bone marker testing does not "tell the whole story of what is going on in bones." Other doctors do use them to guide and assess treatment, as does the oft quoted Keith McCormick. I am curious how many doctors do or do not use bone markers and why.

How many of you have MD's who do the bone marker testing? Have they been helpful? Are they the magic answer to treatment decisions, or should we be more skeptical? Are other blood tests more helpful to you?

Here is a review (based on a symposium lecture) I just found that discusses the complexity of this issue, in the context of kidney disease. I have CKD but am interested in what other factors render certain bone markers less effective. Clearly more research is needed.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5628199/

Excerpts:

For these reasons, especially in CKD, it is important to realize that estimating bone turnover by measuring circulating biomarkers is full of pitfalls, that even a reliable estimate of turnover does not indicate changes in bone balance, and that fracture risk is also dependent on bone features that cannot be assessed by biomarkers, nor even by bone histomorphometry like architecture and bone strength.

and

With all these pitfalls in mind, it is important to stress that one of the largest and most recent analyses confirmed that PTH currently is the most useful biomarker for bone turnover in CKD

and

Biomarkers of bone turnover are promising aids in clinical nephrology practice. A thorough knowledge of what they indicate, of the assay characteristics and of the impact of low estimated glomerular filtration rate (eGFR) are important in interpreting the results. Generally, biomarkers lack sufficient specificity to be able to base far-reaching treatment decisions upon them. However, as follow-up parameters, they may be very useful. Most biomarkers provide mainly an indication of bone formation and, as such, PTH, BSAP and also P1NP can be used. The only useful biomarker that reflects bone resorption in patients with CKD is TRAP5b, but the concentration of this enzyme has not yet been validated with respect to the gold standard, which is bone histomorphometry.